|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C8orf33 |
Gene summary for C8ORF33 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C8orf33 | Gene ID | 65265 |
| Gene name | chromosome 8 open reading frame 33 | |
| Gene Alias | C8orf33 | |
| Cytomap | 8q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q9H7E9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 65265 | C8orf33 | PTC06 | Human | Thyroid | PTC | 9.54e-21 | 5.65e-01 | 0.2057 |
| 65265 | C8orf33 | PTC07 | Human | Thyroid | PTC | 1.29e-32 | 6.44e-01 | 0.2044 |
| 65265 | C8orf33 | ATC09 | Human | Thyroid | ATC | 4.22e-03 | 8.65e-02 | 0.2871 |
| 65265 | C8orf33 | ATC11 | Human | Thyroid | ATC | 4.86e-02 | 1.78e-01 | 0.3386 |
| 65265 | C8orf33 | ATC12 | Human | Thyroid | ATC | 7.69e-20 | 5.37e-01 | 0.34 |
| 65265 | C8orf33 | ATC13 | Human | Thyroid | ATC | 1.05e-36 | 1.02e+00 | 0.34 |
| 65265 | C8orf33 | ATC1 | Human | Thyroid | ATC | 8.89e-04 | 1.20e-01 | 0.2878 |
| 65265 | C8orf33 | ATC2 | Human | Thyroid | ATC | 5.75e-05 | 4.54e-01 | 0.34 |
| 65265 | C8orf33 | ATC4 | Human | Thyroid | ATC | 1.44e-26 | 6.70e-01 | 0.34 |
| 65265 | C8orf33 | ATC5 | Human | Thyroid | ATC | 1.06e-49 | 1.09e+00 | 0.34 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C8orf33 | SNV | Missense_Mutation | novel | c.85N>A | p.Pro29Thr | p.P29T | Q9H7E9 | protein_coding | deleterious_low_confidence(0.01) | benign(0.136) | TCGA-AC-A23G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
| C8orf33 | insertion | Frame_Shift_Ins | novel | c.294_295insCCCGCCCGCGCCCC | p.Val99ProfsTer8 | p.V99Pfs*8 | Q9H7E9 | protein_coding | TCGA-BH-A0E7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| C8orf33 | SNV | Missense_Mutation | novel | c.16N>T | p.His6Tyr | p.H6Y | Q9H7E9 | protein_coding | deleterious_low_confidence(0) | benign(0.342) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| C8orf33 | SNV | Missense_Mutation | novel | c.13N>A | p.Gly5Arg | p.G5R | Q9H7E9 | protein_coding | deleterious_low_confidence(0) | benign(0.043) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| C8orf33 | SNV | Missense_Mutation | rs367787964 | c.437N>A | p.Arg146His | p.R146H | Q9H7E9 | protein_coding | deleterious(0.03) | probably_damaging(0.966) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| C8orf33 | SNV | Missense_Mutation | novel | c.402N>T | p.Gln134His | p.Q134H | Q9H7E9 | protein_coding | deleterious(0) | probably_damaging(0.947) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| C8orf33 | SNV | Missense_Mutation | c.41N>T | p.Ala14Val | p.A14V | Q9H7E9 | protein_coding | tolerated_low_confidence(0.21) | benign(0.003) | TCGA-D5-6529-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | oxaliplatinum+ | SD | |
| C8orf33 | SNV | Missense_Mutation | novel | c.517G>A | p.Glu173Lys | p.E173K | Q9H7E9 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| C8orf33 | SNV | Missense_Mutation | c.327N>T | p.Gln109His | p.Q109H | Q9H7E9 | protein_coding | deleterious(0) | possibly_damaging(0.878) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| C8orf33 | SNV | Missense_Mutation | rs544162421 | c.122N>C | p.Val41Ala | p.V41A | Q9H7E9 | protein_coding | tolerated_low_confidence(0.21) | benign(0.019) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |